Mr. Julien Meissonnier, M.Sc., MBA – Founder, President & CEO
Mr. Meissonnier has 25 years of international business experience in product development, technical service, marketing, business development, consulting, financial and general management. From 2001 to 2008, he was responsible for business development at Evogene, an Israeli agro-biotechnology company. During that period Evogene signed agreements with global leaders (Monsanto, Dupont/Pioneer, Syngenta, Bayer, BASF, Vilmorin…), went public on the Tel Aviv Stock Exchange, and its valuation rose from $1 million to over $100 million. Evogene later listed on the NYSE and reached a company valuation of over $500 million. Earlier he served as Business Development Manager with Sol-Gel Technologies, an Israeli start-up whose valuation rose from $1 million to $12 million in 2 years and signed a strategic agreement with Merck KGaA for its first product. As the founder and manager of R.O.I. Consulting, a fully owned business development consulting company, he also assisted a number of other start-ups, and was responsible for projects for large organizations such as Boeing and NASA. Prior to immigrating to Israel, he was Global Marketing Manager at Ciba-Geigy/Novartis in Switzerland for a $200 million product line. Early in his career, he held product development and technical customer service positions in France and the USA at Rhone-Poulenc.
Mr. Meissonnier holds a Diplôme d'Ingenieur in Physics of Materials from the Institut National des Sciences Appliquées de Lyon, an M.S.E from the Chemical Engineering Dept. of the University of Washington, Seattle, and an MBA from INSEAD, France.
Dr. Harvey Kasdan – Founder & Chief Technology Officer
Prior to co-founding LeukoDx and serving as its CTO, Dr. Kasdan accumulated more than 25 years of experience in in vitro diagnostics development as Director of Product Development, VP R&D and Chief Scientist of IRIS International in California as IRIS grew from a start-up to become the NASDAQ listed world leader in automated urine analysis. Dr. Kasdan drove the development of several medical devices, including several automated urine and blood analyzers, from concept to market launches and prepared four 510(k) FDA submissions that resulted in market launches of products currently generating over $120 million in annual revenues. In 2012, Iris was acquired by Danaher for $338 million and merged into Beckman Coulter. Dr. Kasdan holds BS and MS in Electrical Engineering from MIT and a PhD in Engineering from UCLA. He is the inventor or co-inventor on over 30 patents.
Dr. Tobias Volker – SVP Commercial Operations
Dr. Volker is an accomplished international business executive with expertise in the life science and medical diagnostic field. He has served in high ranking positions in international sales and marketing at major organizations and within different cultures. He is the founder and manager of EXPAN.D, a consultancy company for international healthcare business development. He was Director of International Sales and Marketing and Strategic Alliances at Biosite Inc. from 1998 to 2005; under his guidance, the company successfully extended its point of care franchise (Triage® Cardiac, Triage Microbiology, Triage BNP, etc…) business globally; with a CAGR of >40%, he set up subsidiaries in Germany, France, UK, and the Benelux and extended sales channels to all major countries in Asia and Latin America. Later, as Director of Commercial Operations at Quotient Diagnostics, a startup based in the UK, he successfully led the launch the first product, Quo-Test®. In addition, he significantly expanded the international sales and marketing at other companies such as Jouan (France), Sebia (France), and Cholestech (USA). More recently, Dr. Volker was Senior Vice President at SK Telecom, where he set up the Healthcare R&D group and let the IVD based organic growth. His focus was on developing new immunoassays, new molecular biology based assays for infectious diseases and new point of care testing platforms. Dr. Volker has travelled widely and lived and worked in the USA, France, Switzerland and South Korea. He holds a PhD in Biochemistry from the University of Bordeaux (France) and an MBA from INSEAD (Singapore & Fontainebleau).
Dr. Ephraim Carlebach – SVP R&D
Dr. Carlebach has more than 25 years of diversified experience in medical device development and real-time system design. His most recent prior position was Deputy CEO of Arad Technologies, a TASE listed global technological leader in conventional and ultrasonic flow metering devices and automated read-out systems, which it develops, manufactures, markets, installs and supports. Over three million ARAD products are operating worldwide. Prior to that, he held a series of senior technology positions at medical device companies OrSense (non-invasive measurement of blood parameters) and Applisonix, a TASE listed developer of ultrasound-based medical aesthetics devices. Dr Carlebach spent 10 years as SVP R&D at Oridion Medical, a world leader in the development of CO2 monitoring products which are integrated into patient monitors, defibrillators and infusion pumps of the major medical system vendors including Philips, Draeger, Datascope, Medtronic, Cardinal Health, Covidien, Welch Allyn, Nihon Kohden and Fukuda Denshi. In 2012, Oridion was acquired by Covidien for $346 million. Earlier in his career he spent 16 years in electronics and systems design in image processing and printing industries with Scitex (acquired by Eastman Kodak and Indigo (acquired by HP), rising from Senior Design Engineer to Project Manager and Chief Electronic Engineer & Manager of Technologies. Dr Carlebach holds a Dipl.-Ing. in Electronic Engineering (with highest honors) at the Fachhochschule Aachen, Germany, an M.Sc. in Computer Simulation at the University of Salford, England and a Ph.D. (Eng.) in Electronic Engineering at the University of London.
Allon Reiter, MBA – VP of Business Development
Allon Reiter has been active in the life science industry from 1996. He joined LeukoDx as VP Business Development in June 2013, following the management of two medical device startups, Perflow Medical (thrombectomy device for ischemic stroke) in 2010 and Tulip Medical (solution for obesity) in 2007. From 1998 until 2007, Mr. Reiter was a partner at Giza VC, an Israeli Venture Capital Fund managing over $500 million. Mr. Reiter led and co-led the 16 life-science investments Giza made, resulting in two acquisitions and four IPO’s. From 1996, Mr. Reiter worked in Investment Banking in conjunction with Alex Brown & Sons on life sciences deals. Mr. Reiter holds a BA in Economics from Haifa University and an MBA in Finance and Accounting from Tel Aviv University.
Zion Botesazan – VP of Operations
Zion Botesazan joined LeukoDx in 2013 and built its assembly and manufacturing operation. Prior to joining LeukoDx, Zion spent 17 years with Oridion Medical as R&D Electronics Engineer, Project Leader and R&D Hardware Manager contributing to its growth from a development stage company to the $346 million acquisition by Covidien in 2012. Earlier in his career Zion worked as R&D Electronics Engineer at Minicom and Scitex. Zion Botesazan holds a BSc in Electronics from Tel Aviv University.
Mr. Walter Drimer – Founder & Chairman of the Board
Mr. Drimer is a successful entrepreneur and business development expert with extensive experience in building management and technical teams. He is the President and CEO of Genesis International Group and has been responsible for more than $500 million in transactions over the last 40 years. Throughout his career, Walter has founded several companies and new ventures in both the for-profit and not-for-profit arenas, including Genesis Search Group, Inc., an executive search company specializing in biotech and health care; Innovation Plus LLC, a smart fastener technology company; and American Private Investors Group, an angels club that matches entrepreneurs with private investors.
Prior to LeukoDx, Walter’s most recent project was the 2006 co-founding of Brightsource Energy (www.brightsourceenergy.com
), a solar energy technology enterprise headquartered in the US with its main R&D operations in Israel. Since then Brightsource has raised $615 million of equity from first-tier investors such as Vantage Point, Draper Fisher Juvertson, Morgan Stanley, Google Ventures, BP, Chevron, Statoil Hydro and Alstom. In 2014, its first solar utility scale power plant came online at Ivanpah in the Mohave desert in California; its 377MW, 14.2km2, 173,500 heliostats make it the largest solar power plant in the world. BrightSource has approximately 1.8 gigawatts of future power under contracts with California’s two largest utilities.
Mr. Julien Meissonnier, M.Sc., MBA – Founder, President & Chief Executive Officer
(See above in Management)
Mr. Bruce Sholk – Member of the Board of Directors
Bruce Sholk’s efforts for the past 20 years have been directed at identifying and investing in emerging growth companies. Bruce has been actively involved at the start-up stages of a number of companies that have eventually successfully exited through sale or initial public stock offerings. Bruce’s role has ranged from board member to active involvement in all aspects business management and development. As a managing member of more than 15 private equity funds, principally under Axcel Partners, he has achieved very strong returns for his partners over an extended period of time. Mr. Sholk holds a BS in Business Management and a BA in Advertising from the University of Florida, and an MBA from Carnegie-Mellon University.
Mr. Seymour Liebman, MS., JD. – Member of the Board of Directors
Mr. Seymour Liebman serves as Executive Vice President, Chief Administrative Officer and General Counsel of Canon U.S.A., Inc., as Vice Chairman of Canon Business Solutions, Inc., and as a Senior Executive Officer of Canon Inc. in Japan. For the past 40 years, Mr. Seymour has held a variety of management positions at Canon U.S.A, Inc., and in 2009, became the first non-Japanese individual to be elected to the position of Executive Officer of Canon Inc. in Japan. Mr. Liebman is a Director and/or officer of several Canon subsidiaries and affiliates in the U.S. He is also a Board member of Spartan Bioscience Inc. Mr. Liebman is an attorney admitted to the Bar in New York, New Jersey and the District of Columbia and a C.P.A. He holds a B.A. in Mathematics from Hofstra University, an M.S. in Mathematics from Rutgers University, an M.S. in Accounting from Long Island University and a J.D. from Touro Law School.
Mr. Mark Chess – Member of the Board of Directors
Mr. Mark Chess, a Managing Director for Infinity Equity, was actively involved in establishing the FBR Infinity II Fund in 2001 and the world's first foreign currency fund in China in 2005 (Infinity-CSVC). In 2007-2008, Mr. Chess helped create the strategy and lead the development of the Infinity I-China Fund, taking part in activities that have made Infinity Equity one of China’s most prolific foreign investors. Currently, Mr. Chess manages Infinity’s strategic relationships with institutions in the U.S., including the Infinity-NSF portfolio.
Dr. Marvin Slepian, MD – Founder & Member of the Scientific Advisory Board
Dr. Slepian is a Professor of Medicine (Cardiology), Director of Interventional Cardiology, and Director of the Tissue Engineering Lab at the University of Arizona. Dr. Slepian completed his internal medicine training at NYU-Bellevue in New York where he was a Resident and Chief Resident in Medicine. He is an expert in polymeric biomaterials and local drug delivery. Dr. Slepian was instrumental in the formation of SynCardia Systems, developer of the FDA and CE approved CardioWestTM Temporary Total Artificial Heart and serves as its Chairman.
Prof. Yu-Chong Tai, Ph.D. – Member of Scientific Advisory Board
Pr. Y-C. Tai is Full Professor of Electrical Engineering, Bioengineering and Mechanical Engineering at the California Institute of Technology (Caltech). His research interests include micromachines and/or Micro-electro-mechanical-system (MEMS) technology, microsensors, microactuators, microstructure, MEMS systems, and MEMS science.
Ed Miller, Ph.D. CChem, FRSC – Member of Scientific Advisory Board
Dr. Miller currently serves as Director, Cardiopulmonary Research Laboratory at The Feinstein Institute for Medical Research and Chief, Surgical Immunology, North Shore University Hospital. Dr. Miller's research focuses on the role of immune cells and chemicals in the development and exacerbation of acute lung injury. Dr. Miller received his Doctor of Philosophy in Biochemistry at King's College, University of London and has been elected a Fellow of the Royal Society of Chemistry (FRSC).
Charles Sprung, M.D. – Member of Scientific Advisory Board
Prof. Sprung is the Director of the General Intensive Care Unit in the Department of Anesthesiology and Critical Care Medicine at Hadassah Hebrew University Medical Center where he has worked for the last 20 years, and is currently the Treasurer of European Society of Intensive Care Medicine (ESICM). Professor Sprung has been active in research particularly studying sepsis, septic shock and ethical issues for 30 years. He has participated in many sepsis studies as an investigator, coordinator, clinical evaluation committee member or Safety and Efficacy Monitoring Committee member or chairman.
Dr. Tom Adams, Ph.D. - Member of Scientific Advisory Board
Dr Adams is Chairman of Trovagene (NASDAQ TROV) and Chairman and CEO of Leucadia Technology. He was CTO of Iris International (NASDAQ IRIS, acquired by Beckman Coulter), President of Iris Personalized Medicine and head of Iris Molecular Diagnostics. Iris acquired Leucadia which he founded, a leader in the development of ultrasensitive and specific cancer and infectious disease diagnostic tests. He is Chairman Emeritus and was founder, Chairman and CEO of Genta Inc. (NASDAQ, GNTA), a developer of cancer drugs that he took public in 1991 (reaching a $1.5B market cap). He was founder, Chairman and CEO of Gen-Probe Inc. (NASDAQ, GPRO), the leader in DNA probe diagnostics that he took public in 1987 (recently acquired for $3.7B). He was Sr. VP and CTO of Hybritech Inc., the leader in monoclonal antibody diagnostics and therapeutics (sold to Eli Lilly for about $1.0B). He was the first outside director for Applied Molecular Evolution (sold to Lilly for $400m). Earlier, he was VP of R&D at Technicon Instruments Corp., a leader in clinical diagnostic systems; Director of R&D at the Hyland division of Baxter Laboratories and Group Leader in R&D with the DuPont Company. He is the author of numerous patents and publications in diverse areas of biomedical science and a recipient of a 1992 DuPont Award for Technical Achievement. He was a finalist for the Entrepreneur of the year Award in 1992. He was a member and Chairman of numerous health care industry committees with HIMA, PMA and NCCLS. He received his Ph.D. degree in Biochemistry from the University of California at Riverside.
Dr. David King – Member of Scientific Advisory Board
David King is currently Executive Vice President, R&D at Integenx based in Pleasanton, CA. David has over 20 years’ experience in the diagnostics and life science tools industries with a focus on identifying and developing high-value products for decentralized clinical and research applications in cell biology and genomics. Prior to Integenx, David was Vice President of Product Development at Affymetrix, where he led introduction of next-generation instrument platforms, as well as genome and transcriptome analysis products. David also served as Vice President, R&D and Operations at Guava Technologies (acquired by EMD Millipore Corporation). At Guava, David commercialized research and clinical flow cytometry instrument platforms and applications and expanded Guava’s international service and support organization. He holds a Ph.D. from Stanford University and a B.Sc.(Hons) from University of New South Wales, Australia.
Dr. Bruce Davis, MD – Member of the Scientific Advisory Board
A well respected hematopathologist with over 25 years of experience in flow cytometry diagnostics in particular. He is also Founder and President of Trillium Diagnostics, a company that develops diagnostic assays for clinical cytometry and laboratory hematology. He leads research and development of new diagnostic products for laboratory hematology and filed intellectual property on a flow cytometric assay for quantification of CD64 for Sepsis the biomarker used in the first LeukoDx cartridge. Dr. Davis has over 100 peer-reviewed publications and serves on the editorial boards for journals of cytometry and laboratory hematology and has provided consultation to a number of medical diagnostics companies. He received his BS in from Cornell University in New York and his MD from University of Connecticut.